Abstract:In 2022, the US National Institute on Drug Abuse reported that there were 81 806 deaths related to opioids, a 64% increase between 2019 and 2022. 1 Of concern are people experiencing homelessness (PEH), who have 12 times the risk of drug overdose mortality compared with the general US population. 2 Although medications to treat opioid use disorder (OUD), such as buprenorphine, are effective and safe, PEH are less likely to receive these treatments due to patient-, clinician-, and system-level barriers. 3 Although delivery of medication for OUD treatment through office-based addiction treatment programs has been reported to reduce all-cause mortality, 4 PEH experience unique barriers that prevent them from continuing addiction treatment at brick-and-mortar clinics. A shelter-based opioid treatment (SBOT) program provides an alternative approach to improve access to medications for OUD (eg, buprenorphine) by delivering on-site care at a family shelter for PEH. Initial findings on a SBOT program in Boston, Massachusetts, 5 reported that this type of program reduced illicit substance abuse, reduced opioid overdose, and improved employment. However, the value assessment (eg, cost-effectiveness) and affordability (eg, budget impact) of SBOT programs have yet to be ascertained and are important factors for decision-making. In their study, Chatterjee et al 6 evaluated the cost-effectiveness and budget impact of SBOT for PEH from the US health care and societal perspectives. Using dynamic state-transition models, Chatterjee et al 6 reported that SBOT for PEH was not only cost-effective over the lifetime horizon, but also affordable to health care payers and society over a 10-year period, despite the expected increase in costs due to offsets by averted incarcerations, overdoses, and deaths. Pharmacoeconomic models are useful for policymakers who struggle with limited information to make informed decisions about public health. In particular, the intersection between homelessness and OUD is a complicated and challenging public health crisis that requires careful synthesis of the available data. Given that no long-term study is available on opioid treatment among PEH, simulations such as the one developed by Chatterjee et al 6 provide valuable projections on the clinical and economic benefit of public health interventions. However, models may not capture all the relevant scenarios or conditions, particularly with PEH and OUD, and policymakers will need to consider other factors when making decisions about optimal strategies to address the opioid crisis among PEH. PEH encounter more barriers to receiving treatment for OUD than those who are housed; however, once receiving treatment, PEH experience similar clinical benefits. 3 Therefore, reducing barriers to access is an important public health strategy to mitigate opioid-related morbidity and mortality among PEH. By delivering addiction treatment to the shelters where PEH are staying, SBOT has an advantage over other forms of interventions, such as brick-and-mortar treatment centers. However, several issues persist despite evidence supporting implementation and sustainability of SBOT for PEH, such as addressing the root cause of the problem, adherence and retention in treatment, and location of SBOT programs. According to a report by the National Alliances to End Homelessness based on data from the US Department of Housing and Urban Development, 7 the estimated prevalence of PEH and those living in shelters have increased by 6% between 2017 and 2022. There is debate regarding the association of homelessness with OUD, which may unfairly lay blame on PEH and detract from the actual conversation of finding and implementing solutions. According to Doran et al, 8 the underlying association of opioid addiction with PEH appears to be bidirectional and arguments for a unidirectional association only further stigmatization of a marginalized population. What is known is that a lack of housing is significantly associated with opioid-related deaths. For instance, Bradford et al 9 reported that a 1% increase in homelessness was associated with an increase of 68 opioid-related deaths in a metropolitan continuum-of-care area. Stable housing is an important factor in the comprehensive OUD treatment paradigm for PEH. Without stable housing, there is a higher likelihood of treatment interruption, relapse, and death. To effectively address OUD among PEH, policymakers will need to tackle both housing and OUD treatment. This requires commitment and coordination by local government and public health agencies to implement housing programs (eg, Housing First) and expansion of addiction treatment services to address OUD for PEH. Another concern is adherence and retention with OUD treatment among PEH. Adherence with office-based -Abstract Truncated-

Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters

Value of Shelter-Based Opioid Treatment Among People Experiencing Homelessness

Emergency Department Access to Buprenorphine for Opioid Use Disorder

Facilitating exit from encampments: combining low-barrier transitional housing with stabilizing treatment for substance related problems

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA

Enhancing Outcomes in Opioid Use Disorder Treatment: An Economic Evaluation of Improving Medication Adherence for Buprenorphine Through Blister-Packaging

Impact of Emergency Department-Initiated Buprenorphine on Repeat Emergency Department Utilization

Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder

Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic randomized trial

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

There goes the neighborhood? The public safety enhancing effects of a mobile harm reduction intervention

The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom

Perspectives of Clinicians and Staff at Community-Based Opioid Use Disorder Treatment Settings on Linkages With Emergency Department-Initiated Buprenorphine Programs

Opening the "black box": Four common implementation strategies for expanding the use of medications for opioid use disorder in primary care

Drug Overdose Mortality Among People Experiencing Homelessness, 2003 to 2018

Healthcare utilisation and associated costs for methadone versus buprenorphine recipients: Examination of interlinked primary and secondary care electronic health records in England

Reprint of: Impact of outpatient pharmacist dispensing in an opioid use disorder clinic

Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care

Buprenorphine Use in the Military Health System (MHS)

Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model

Buprenorphine prescription and treatment initiation through preemptive outreach and telehealth consultation with emergency medicine providers